A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild Alzheimer's disease found a small advantage for acetyl-L-carnitine over placebo on clinical and psychometric measures.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
emerging
Claim: Meta-analysis: small effect of acetyl-L-carnitine over placebo in MCI and mild Alzheimer's diseasestanding
resolved
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.
Claim: Acetyl-L-carnitine increased taxane-induced neuropathy at 24 weeks in a placebo-controlled trialstanding
resolved
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.